KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Operating Expenses: 2016-2024

Historic Operating Expenses for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to $7.2 billion.

  • Moderna's Operating Expenses fell 33.95% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 billion, marking a year-over-year decrease of 26.74%. This contributed to the annual value of $7.2 billion for FY2024, which is 35.23% down from last year.
  • As of FY2024, Moderna's Operating Expenses stood at $7.2 billion, which was down 35.23% from $11.1 billion recorded in FY2023.
  • Moderna's Operating Expenses' 5-year high stood at $11.1 billion during FY2023, with a 5-year trough of $1.6 billion in FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $9.8 billion (2022), whereas its average is $9.4 billion.
  • As far as peak fluctuations go, Moderna's Operating Expenses spiked by 230.46% in 2021, and later crashed by 35.23% in 2024.
  • Over the past 5 years, Moderna's Operating Expenses (Yearly) stood at $1.6 billion in 2020, then spiked by 230.46% to $5.2 billion in 2021, then soared by 90.20% to $9.8 billion in 2022, then climbed by 12.64% to $11.1 billion in 2023, then slumped by 35.23% to $7.2 billion in 2024.